| Biomarker ID | 355 |
| PMID | 18559597 |
| Year | 2008 |
| Biomarker | Endoglin |
| Biomarker Basis | Concentration Based (ng/ml) |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Increased with Biochemical Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: (Rate Ratio: 2.97); Multivariate: (Rate Ratio: 2.27) |
| Effect on Pathways | Pathways Include:- ALK1 pathway,HIF-1 transcriptional activity in hypoxia,TGF-beta signaling pathway |
| Experiment | Biochemical Recurrence Vs no Recurrence in 5 years |
| Type of Biomarker | Prognostic |
| Cohort | 423 patients treated with radical prostatectomy and bilateral lymphadenectomy for clinically localized prostatic adenocarcinoma were chosen. |
| Senstivity | NA |
| Specificity | NA |
| AUC | Univariate: Concordance Index: 64.9; Multivariate: Concordance Index: 71.9 |
| Accuracy | NA |
| Level Of Significance | Univariate: p<0.001Multivariate: p=0.002 |
| Method Used | enzyme immunoassays |
| Clinical | No |
| Remarks | Univariate Analysis. Biochemical recurrence was defined as a sustained elevation, on two or more occasions, of serum total prostate-specific antigen >0.2 ng/mL |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | ENG |